We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byDraga Roberta Dochioiu
Modified over 4 years ago
Non-Small Cell Lung Cancer Resection in Lymphoma Patients Min P. Kim, MD, Arlene M. Correa, PhD, Stephen G. Swisher, MD, Wayne L. Hofstetter, MD, Reza J. Mehran, MD, David C. Rice, MB, BCh, Garrett L. Walsh, MD, Jeremy Erasmus, MD, Cesar Moran, MD, Ara A. Vaporciyan, MD, Jack A. Roth, MD The Annals of Thoracic Surgery Volume 90, Issue 1, Pages (July 2010) DOI: /j.athoracsur Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 The 5-year overall survival rate for the lymphoma group with lung cancer (35%) was significantly lower than that for the nonlymphoma group with lung cancer (67%; p = 0.04). The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 There was no significant difference in lung cancer-specific survival (p = 0.56). The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 In the lymphoma group, the 5-year overall survival did not differ significantly between patients with active lymphoma at the time of lung cancer resection (active lymphoma) and patients with a history of lymphoma but no active lymphoma at time of lung cancer resection (history of lymphoma; p = 0.07). The Annals of Thoracic Surgery , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions
Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic.
The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution Linda W. Martin, MD, Arlene.
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer
History of Multiple Previous Malignancies Should Not Be a Contraindication to the Surgical Resection of Lung Cancer Pierre-Benoit Pagès, MD, Pierre Mordant,
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.
Joshua E. Rosen, BASc, Hari B
Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: Significance of microscopically positive circumferential radial margins
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Puja Gaur, MD, Wayne L. Hofstetter, MD, B
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population Edmund S. Kassis, MD, Ara A. Vaporciyan,
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Super-Charged Pedicled Jejunal Interposition Performance Compares Favorably With a Gastric Conduit After Esophagectomy Elizabeth H. Stephens, MD, PhD,
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,
Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases
© 2023 SlidePlayer.com Inc. All rights reserved.